Ravi Kant Upadhyay*

Department of Zoology, Deen Dayal Upadhyaya Gorakhpur University, Gorakhpur, UP, India

*Corresponding Author: Ravi Kant Upadhyay, Department of Zoology, Deen Dayal Upadhyaya Gorakhpur University, Gorakhpur, UP, India.

Received: June 07, 2021; Published: June 24, 2021

Citation: Ravi Kant Upadhyay. “Climate Induced, Opportunistic Nosocomial Fungal Infections: Its Prevention and Control". Acta Scientific Clinical Case Reports 2.7 (2021): 72-84.

Abstract

This paper explains recently emerged climate induced opportunistic nosocomial infections in detail with its prevention and control. All these fungal infections have been emerged all of a sudden in hospitalized patients those who are under clinical care, recovered and in home isolation. Recent corona virus pandemic raised this problem as the high dosages of steroids, calcium, zinc and hot vapors inhalation prepared humid a platform on which fungal spores have grown in nasal sacs, eyes, ears, and transferred to internal organ systems lungs, brain and blood, caused septicemia and death of patients. Most of the dermatophytes grow over skin surface and utilize epidermal cells of skin, nails and hair follicles and cause black lesions. Invasive fungal disease mainly mucormycosis and others evoke all of sudden due to immunological defects, use of concomitant immunomodulators or immunosuppressive therapies or steroids to cure Covid-19 patients. For avoiding entry of spores in sinuses or lungs through inhalation of air, double layered mask is essential. This article suggests complete avoidance of steroids by autoimmune or immune deficient patients. For better recovery an early diagnosis, treatment by using fast acting anti-fungal agents and surgery of mucor-mycosis patients are highly important.

Keywords: Invasive Fungal Diseases; Molds; Opportunistic Nosocomial Infections; Aspergillosis; Candidiasis; Mucor-Mycosis

Bibliography

1. Spinello Antinori., et al. Massimo Galli 16 (2020): 1-203.
2. Guillermo Quindós., et al. “Chapter 17 - State of the Art in the Laboratory Methods for the Diagnosis of Invasive Fungal Diseases, Microbiology for Surgical Infections, Diagnosis, Prognosis and Treatment”, Academic Press (2014): 281-297.
3. Wucherpfenning KW. “Mechanism of induction of autoimmunity by infectious agents”. Journal of Clinical Investigation 108 (2001): 1097.
4. Joshua Perlroth., et al. “Nosocomial fungal infections: epidemiology, diagnosis, and treatment”. Medical Mycology4 (2007): 321-346.
5. Badiee P and Hashemizadeh Z. “Opportunistic invasive fungal infections: diagnosis and clinical management”. Indian Journal of Medical Research2 (2014): 195-204.
6. Bolognia Jean L., edition. Dermatology (2003): 1174-1185.
7. Freedberg Irwin M. Fitzpatrick's Dermatology in General Medicine. 6^th edition (2003): 1251.
8. Arnold HL., et al. “Andrew’s Diseases of the Skin” Clinical Dermatology, edition. 8. Philadelphia, Saunders (1990): 300-301.
9. Reynolds RD., et al. “Exacerbation of tinea corporis during treatment with 1% clotrimazole/0.05% betamethasone diproprionate (lotrisone)”. The American Journal of Diseases of Children 145 (1991): 1224-1225.
10. Radentz WH and Yanase DJ. “Papular lesions in an immunocompromised patient: Trichophyton rubrum granulomas (Majocchi’s granuloma)”. Archives of Dermatological 129 (1993): 1189-1190.
11. Sobel JD. “Vulvovaginal candidosis external icon”. Lancet 369 (2007): 1961-1971.
12. Gonçalves B., et al. “Vulvovaginal candidiasis: epidemiology, microbiology and risk factors external icon”. Critical Reviews in Microbiology 42 (2016): 905-927.
13. Pappas PG., et al. “Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases” Society of America external icon”. Clinical Infectious Diseases 62 (2016): e1-50.
14. Benedict K., et al. “Estimation of Direct Healthcare Costs of Fungal Diseases in the United States”. Clinical Infectious Diseases11 (2019): 1791-1797.
15. Alastruey-Izquierdo A., et al. “Treatment of chronic pulmonary aspergillosis: Current standards and future perspectives”. Respiration 6 (2018): 1-12.
16. Denning DW., et al. “Case definition of chronic pulmonary aspergillosis in resource-constrained settings”. Emerging Infectious Diseases 24 (2018): e171312.
17. Rees JR., et al. “The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993: Results of population-based laboratory active surveillance”. Clinical Infectious Diseases 27 (1998): 1138-1147.
18. Jenks JD and Hoenigl M. “Treatment of Aspergillosis”. Journal of Fungi3 (2018): 98.
19. Richardson M. “The ecology of the Zygomycetes and its impact on environmental exposure”. Clinical Microbiology and Infection5 (2009): 2-9.
20. Roden MM., et al. “Epidemiology and outcome of zygomycosis: a review of 929 reported cases”. Clinical Infectious Diseases5 (2005): 634-653.
21. Spellberg B., et al. “Novel perspectives on mucormycosis: pathophysiology, presentation, and management”. Clinical Microbiology Reviews3 (2005): 556-569.
22. Al-Ajam MR., et al. “Mucormycosis in the Eastern Mediterranean: a seasonal disease”. Epidemiology and Infection2 (2006): 341-346.
23. Talmi YP., et al. “Rhino-orbital and rhino-orbito-cerebral mucormycosis”. Otolaryngology-Head and Neck Surgery1 (2002): 22-31.
24. Sivagnanam S., et al. “Seasonal clustering of sinopulmonary mucormycosis in patients with hematologic malignancies at a large comprehensive cancer center”. Antimicrobial Resistance and Infection Control 6 (2017): 123.
25. Petrikkos G., et al. “Epidemiology and clinical manifestations of mucormycosis”. Clinical Infectious Diseases1 (2012): S23-34.
26. Ribes JA. “Zygomycetes in human disease”. Clinical Microbiology Reviews 13 (2000): 236-301.
27. Song Y., et al. “Mucormycosis in renal transplant recipients: review of 174 reported cases”. BMC Infectious Diseases1 (2017): 283.
28. Walsh TJ., et al. “Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis)external icon”. Clinical Infectious Diseases1 (2012): S55-60.
29. Abbasi-Oshaghi E., et al. “Diagnosis and treatment of coronavirus disease 2019 (COVID-19): Laboratory, PCR, and chest CT imaging findings”. International Journal of Surgery 79 (2020): 143-153.
30. Gordana Mirchevska., et al. “Evaluation of panfungal marker (1,3)-D glucanin diagnosis of invasive infections with Candia species”. Macedonian Medical Review2 (2016): 75-81.
31. Abassi M., et al. “Cryptococcal Meningitis: Diagnosis and Management Update”. Current Tropical Medicine Reports 2 (2015): 90-99.
32. Quindós G., et al. “The continuous changes in the aetiology and epidemiology of invasive candidiasis: from familiar Candida albicans to multi resistant Candida auris”. International Microbiology 21 (2018): 107-119.
33. Pappas PG., et al. “Invasive fungal infections among organ transplant recipients: Results of the transplant-associated infection surveillance network (TRANSNET)”. Clinical Infectious Diseases 50 (2010): 1101-1111.
34. Brizendine KD., et al. “Antifungal prophylaxis in solid organ transplant recipients external icon”. Expert Review of Anti-infective Therapy 5 (2011): 571-581.
35. Rogers TR., et al. “Antifungal prophylaxis during treatment for haematological malignancies: are we there yet? external icon”. British Journal of Haematology 6 (2011): 681-697.
36. Avery RK and Michaels MG. “AST Infectious Diseases Community of Practice. Strategies for safe living following solid organ transplantation-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice”. Clinical Transplantation9 (2019): e13519.
37. “Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients”. The Morbidity and Mortality Weekly Report 49.10 (2000): 1-125.
38. Chmutina K and Von Meding JA “Dilemma of Language: “Natural Disasters” in Academic Literature”. International Journal of Disaster Risk Science 10 (2019): 283-292.
39. Stringer JR., et al. “A new name (Pneumocystis jiroveci) for Pneumocystis from humans”. Emerging Infectious Diseases9 (2002): 891-896.
40. Roux A., et al. “Pneumocystis jirovecii pneumonia in patients with or without AIDS France”. Emerging Infectious Diseases 20 (2014): 1490-1497.
41. Gold JAW., et al. “Possible Diagnostic Delays and Missed Prevention Opportunities in Pneumocystis Pneumonia Patients Without HIV: Analysis of Commercial Insurance Claims Data-United States, 2011-2015”. Open Forum Infectious Diseases7 (2020): ofaa255.
42. Harris JR., et al. “Pneumocystis jirovecii pneumonia: current knowledge and outstanding public health issues”. Current Fungal Infection Reports 4 (2010): 229-237.
43. Kaplan JE., et al. “Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy”. Clinical Infectious Diseases1 (2000): S5-14.
44. Morris A., et al. “Current epidemiology of Pneumocystis pneumonia external icon”. Emerging Infectious Diseases 10 (2004): 1713-1720.
45. Edman JC., et al. “Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi”. Nature 334 (1988): 519-522.
46. Kovacs JA., et al. “Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immuno deficiencies”. Annals of Internal Medicine 100 (1984): 663-671.
47. Medrano FJ., et al. “Pneumocystis jirovecii in general population”. Emerging Infectious Diseases 11 (2005): 245-250.
48. Karageorgopoulos DE., et al. “Accuracy of beta-D-glucan for the diagnosis of Pneumocystis jirovecii pneumonia: a meta-analysis”. Clinical Microbiology and Infection 19 (2013): 39-49.
49. Gianella S., et al. “Molecular evidence of inter-human transmission in an outbreak of Pneumocystis jirovecii pneumonia among renal transplant recipients”. Transplant Infectious Disease 12 (2010): 1-10.
50. Schmoldt S., et al. “Molecular evidence of nosocomial Pneumocystis jirovecii transmission among 16 patients after kidney transplantation”. Journal of Clinical Microbiology 46 (2008): 966-971.

Copyright: © 2021 Ravi Kant Upadhyay. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.